Adverse events within 7 days of administration; study participants aged 18-55 years | ||
Adverse event reported |
Dose 1 (%) |
Dose 2 (%) |
Local erythema |
4.5 |
5.9 |
Local swelling |
5.8 |
6.3 |
Pain at injection site |
83.1 |
77.8 |
Temperature ≥38°C |
3.7 |
15.8 |
Fatigue |
47.4 |
59.4 |
Headache |
41.9 |
51.7 |
Chills |
14.0 |
35.1 |
Vomiting |
1.2 |
1.9 |
Diarrhea |
11.1 |
10.4 |
New or worsened myalgia |
21.3 |
37.3 |
New or worsened arthralgia |
11.0 |
21.9 |
Adverse events within 7 days of administration; study participants aged ≥56 years | ||
Adverse event reported |
Dose 1 (%) |
Dose 2 (%) |
Local erythema |
4.7 |
7.2 |
Local swelling |
6.5 |
7.5 |
Pain at injection site |
71.1 |
66.1 |
Temperature ≥38°C |
1.4 |
10.9 |
Fatigue |
34.1 |
50.5 |
Headache |
25.2 |
39.0 |
Chills |
6.3 |
22.7 |
Vomiting |
0.5 |
0.7 |
Diarrhea |
8.2 |
8.3 |
New or worsened myalgia |
13.9 |
28.7 |
New or worsened arthralgia |
8.6 |
18.9 |
Adapted from N Engl J Med. 2020 Dec 10. doi: 10.1056/NEJMoa2034577 and the Pfizer-BioNTech COVID-19 Vaccine [COVID-19 mRNA Vaccine] Product Monograph. |